Bank of America Reviews a Survey on Auxilium Pharmaceutical

Bank of America has published a report on Auxilium Pharmaceuticals (NASDAQ: AUXL) reviewing the results of a survey the bank had commissioned.

In the report, Bank of America wrote, "We commissioned a survey of 75 docs that treat hypogonadism (low testosterone) to help assess the outlook for AUXL's Testim. Overall, the docs expect their prescribing of testosterone replacement (TRT) drugs to grow over the next year, and expect Testim share to decline as LLY's Axiron and ENDP's Fortesta gain share. As always, we caution investors that the views of these docs may not be indicative of the overall market."

Bank of America rated Auxilium a BUY with a price target of $27.00. Auxilium closed Thursday at $18.85.